Monash

Monash University, Australia's Largest University, Selects Ellucian Banner SaaS to Elevate Technology Operations

Retrieved on: 
Sunday, October 29, 2023
Information system, Education, Research, Monash, University, Student, Monash University, Monash University Malaysia, Software as a service, Management

RESTON, Va., Oct. 29, 2023 /PRNewswire/ -- Ellucian, the leading tertiary education technology solutions provider, today announced that Monash University, among the world's top universities with a global network of talent and campuses, will implement Ellucian Banner SaaS, a modern Student Management System. Monash University joins more than 1,600 institutions worldwide leveraging Ellucian SaaS solutions.

Key Points: 
  • RESTON, Va., Oct. 29, 2023 /PRNewswire/ -- Ellucian , the leading tertiary education technology solutions provider, today announced that Monash University , among the world's top universities with a global network of talent and campuses, will implement Ellucian Banner SaaS, a modern Student Management System.
  • Monash University joins more than 1,600 institutions worldwide leveraging Ellucian SaaS solutions.
  • "Ellucian's Banner SMS platform is a cornerstone in the Monash University ambition to create a seamless experience for students from enrolment to graduation," Trevor Woods, Vice-President of Services, Monash University said.
  • "Monash University is excited to partner with Ellucian to realize these possibilities."

Entrinsic Bioscience Announces Breakthrough Innovation for Next Generation Sports and Recreational Rehydration™ Beverages

Retrieved on: 
Tuesday, October 24, 2023
GI, Trial of the century, Sport, Exertion, EBS, Health, Inflammation, Permeability, Monash, Dehydration, Ultra, Monash University, Vaccine, Dietary supplement, MD

NORWOOD, Mass., Oct. 24, 2023 /PRNewswire/ -- Entrinsic Bioscience (EBS) has published a ground-breaking clinical study demonstrating the potential for next generation sports and rehydration beverages, powered by its new Ultra-Hydrating HeatDefense™ formula which promotes dual action rapid rehydration with new levels of heat protection during sports, physical exertion and high heat stress. This formula also harnesses the power of eight times the number of electrolyte transporters resulting in more complete and faster rehydration. Unlike glucose-based beverages which utilize only one transporter, this formula will provide consumers superior electrolyte and water absorption with increased heat protection, immune support and inflammation reduction during exertional heat stress.

Key Points: 
  • This formula also harnesses the power of eight times the number of electrolyte transporters resulting in more complete and faster rehydration.
  • Unlike glucose-based beverages which utilize only one transporter, this formula will provide consumers superior electrolyte and water absorption with increased heat protection, immune support and inflammation reduction during exertional heat stress.
  • "We are excited to announce the results of this study demonstrating the potential to transform traditional sports and recreational beverages around the globe," stated Stephen Gatto, chairman and CEO of Entrinsic Bioscience.
  • New benefits delivered by the EBS amino acid-based beverages during the HEAAT study include:
    Protection of the intestinal barrier during sport, physical exertion and heat

Daily aspirin doesn't prevent strokes in older, healthy people after all

Retrieved on: 
Wednesday, July 26, 2023
Blood pressure, Bleeding, Accident, Stroke, Oxygen, Cholesterol, Monash University, Clinical trial, Head, Research, Brain, Medicine, Falls, History, Aspirin, Stomach, Clopidogrel, Pain, Genetics, Dipyridamole, Time, Risk, Frailty, Blood, Ibuprofen, Ageing, Monash, Fentanyl, Skin, Safety, Injury, Dietary supplement, Pharmaceutical industry, Birth control, Medicinal plants, Vaccine

The daily use of low dose aspirin has been a mainstay of preventing strokes for decades.

Key Points: 
  • The daily use of low dose aspirin has been a mainstay of preventing strokes for decades.
  • While there has always been a risk of bleeding associated with aspirin use, the benefits were thought to outweigh the risk.
  • Now new research led by Monash University has shown daily, low-dose aspirin doesn’t prevent strokes in relatively healthy people aged over 70.

Why has aspirin been used to prevent strokes?

    • They are what stop you from continuously bleeding any time you have a cut or scrape on your skin.
    • Because aspirin acts on platelets, it can help prevent the clots that can lead to a stroke.
    • But because aspirin acts on platelets, it can also increase the risk of unwanted bleeding, usually in the stomach.

Findings of the Monash trial

    • New research from Australia and the United States reports results from the Aspirin in Reducing Events in the Elderly (ASPREE) trial.
    • When compared with placebo, aspirin didn’t reduce or increase the risk of stroke.
    • Read more:
      Daily low-dose aspirin doesn't reduce heart-attack risk in healthy people

      These findings are not entirely new.

    • Research published five years ago based on the same ASPREE trial showed a similar result: a higher rate of bleeding among those taking low-dose aspirin compared with placebo.

What are the study’s limitations?

    • So we don’t know whether the results are translatable to people with different ethnic backgrounds.
    • Younger age groups were not studied either, so we cannot make any conclusions about their use of low dose aspirin to prevent stroke.

I’m taking aspirin, what should I do?

    • If you’re taking daily low-dose aspirin and are concerned by the results of the study, it’s important you don’t just stop taking your medicine.
    • For people who are at high risk of having a stroke, or have previously had one, low-dose aspirin may remain their treatment of choice despite the slight bleeding risk.
    • Nial regularly consults to industry on issues to do with medicine risk assessments, manufacturing, design, and testing.

EQS-News: Eckert & Ziegler: Recognized Australian Endocrine & Hypertension Center Joins International Groups with a Clinical Trial of PentixaPharm’s Primary Aldosteronism Lead Candidate

Retrieved on: 
Tuesday, May 9, 2023
Blood pressure, Primary aldosteronism, CT, CXCR4, Heart failure, Gland, Hypertension, Stroke, APA, TecDAX, BAH, Nuclear medicine, File association, Trial of the century, Investigator, Aldosterone, Patient, Risk, Hyperplasia, Adenoma, Chief medical informatics officer, Surgeon, Hudson Institute, ISIN, Principal, Monash, AVS, Eckert, Pharmaceutical industry, Medical imaging, Gallium

Primary Aldosteronism (PA) refers to the hypersecretion of aldosterone, a hormone that increases blood pressure and consequently leads to high vascular morbidity including stroke and heart failure.

Key Points: 
  • Primary Aldosteronism (PA) refers to the hypersecretion of aldosterone, a hormone that increases blood pressure and consequently leads to high vascular morbidity including stroke and heart failure.
  • It would most likely have a large impact on clinical practice and enable a large number of hypertension patients to be cured.
  • The study in Australia is in line with clinical activities in Europe and in the USA, which are supported by PentixaPharm.
  • [68Ga]Ga-PentixaFor is being developed by Eckert & Ziegler's subsidiary PentixaPharm GmbH also as a superiorly sensitive diagnostic for a portfolio of hematooncological malignancies.

GI OnDEMAND Partnership with Mindset Health/Nerva Makes It Easy for Gastroenterology Practices Nationwide to Deliver Gut-Directed Hypnotherapy to Their IBS Patients

Retrieved on: 
Thursday, October 20, 2022
Genetic counseling, Education, Therapy, American College of Gastroenterology, Diagnosis, THE, OnDemand, Patient, Doctor of Psychology, Scientific method, Program, Mindset Network, GI, Charlotte Convention Center, Partnership, University, FUTURE, IBS, ACG, Irritable bowel syndrome, Health, Practice management software, Department, Founder, College, Gold, Overalls, Genetic testing, American College, Monash, FODMAP, Monash University, Health care, Medical device, Medicine, Gastroenterology

GI OnDEMAND, a joint venture between the American College of Gastroenterology and Gastro Girl, Inc., now provides GI OnDEMAND and ACG members nationwide an evidence-based program to deliver gut-directed hypnotherapy to their IBS patients.

Key Points: 
  • GI OnDEMAND, a joint venture between the American College of Gastroenterology and Gastro Girl, Inc., now provides GI OnDEMAND and ACG members nationwide an evidence-based program to deliver gut-directed hypnotherapy to their IBS patients.
  • Nerva is a self-directed digital therapeutic with proven benefits that patients will find easy to use and effective."
  • I look forward to working tirelessly with GI OnDEMAND to enable the widespread use of Nerva to some 1 billion + IBS sufferers worldwide."
  • Partnering with Dr. Simone Peters, Nerva was created to increase access to one of the most effective options for IBS patients; gut-directed hypnotherapy.

BLOOMBERG PHILANTHROPIES AND THE SAGOL FAMILY LAUNCH THE BLOOMBERG-SAGOL CENTER FOR CITY LEADERSHIP AT TEL AVIV UNIVERSITY

Retrieved on: 
Sunday, April 3, 2022
Family, Hedera, Research, Public health, School, Monash, Knowledge, Twitter, Wilderness Inner-City Leadership Development, TAU, Education, HBS, Metabolism, Transport, Harvard Kennedy School, Harvard University, Humanities, Terrorism, Quality of life, Bloomberg Philanthropies, Harvard Business School, Student, Policy, Leadership, Budget, Life, 108th Training Command (Initial Entry Training), Multimedia, Business, Program, Bloomberg L.P., Research program, Ageing, Instagram, Organization, Sagol, TEL, Health, City, Columbia University, Bloomberg, Community education, Learning, HKS, YouTube, Decision-making, Management, Medicine, Nightclub, Environment, Facebook, Tel Aviv University

TEL AVIV, Israel, April 3, 2022 /PRNewswire/ -- Bloomberg Philanthropies and The Sagol Family today announced a major new effort to strengthen local leadership across Israel through The Bloomberg-Sagol Center for City Leadership at Tel Aviv University. Inspired by the Bloomberg Harvard City Leadership Initiative, the new program aims to help mayors of cities across Israel – north and south, large and small, Jewish- and Arab-led – deliver better and more equitable public services to residents, strengthen social bonds, and deepen ties to the global community of innovative city leaders.

Key Points: 
  • In 2016, Bloomberg Philanthropies and Harvard University established the Bloomberg Harvard City Leadership Initiative , an unparalleled effort by Harvard Kennedy School (HKS) and Harvard Business School (HBS) to build the leadership capabilities of mayors and their teams.
  • Yossi Sagol began working with Bloomberg Philanthropies in 2018 to develop an Israel-based program similar to the Bloomberg Harvard City Leadership Initiative that could strengthen the country from the local level up.
  • The Bloomberg-Sagol Center for City Leadership will focus on developing the leadership and management skills of mayors and their senior aides, while strengthening city hall operations.
  • Tel Aviv the city and Tel Aviv the university are one andthe same a thriving Mediterranean center of diversity and discovery.

Open Infrastructure Foundation Welcomes Six New Associate Members

Retrieved on: 
Wednesday, February 16, 2022
Cloud, Australian Research Data Commons, Adoption, OSI, HPC, Foundation, Health eResearch Centre, École Polytechnique, Télécom Paris, Massachusetts Green High Performance Computing Center, Software, Knowledge, Language, OSUOSL, AI, Operate, Awareness, Monash University, Research, Associate, Industry, POWER, Education, Movement, MOC, OpenStack, ARDC, The Open Source Definition, Open Source Initiative, Berkeley Open Infrastructure for Network Computing, Cloud computing, Organization, Artifact, OIF, AArch64, OSD, Monash, University, Oregon State University, Laboratory, Mobile phone, Medical device, Internet service provider, University of Massachusetts Amherst

AUSTIN, Texas, Feb. 16, 2022 /PRNewswire-PRWeb/ --The Open Infrastructure (OpenInfra) Foundation today announced six new members of its Associate Member category : ARDC (Nectar Cloud), Oregon State University, Monash University, Open Source Initiative, Telecom Paris and University of Massachusetts Amherst.

Key Points: 
  • AUSTIN, Texas, Feb. 16, 2022 /PRNewswire-PRWeb/ --The Open Infrastructure (OpenInfra) Foundation today announced six new members of its Associate Member category : ARDC (Nectar Cloud), Oregon State University, Monash University, Open Source Initiative, Telecom Paris and University of Massachusetts Amherst.
  • This Associate category of Foundation members was added by the OpenInfra Foundation board in 2021 to recognize and collaborate more closely with academic and public research institutions and non-profit organizations that use, build or sustain open infrastructure.
  • "Engagement with the Open Infrastructure community has been crucial to the success of the ARDC Nectar Research Cloud, and we are excited to become an Associate Member of the OpenInfra Foundation."
  • Learn more about attendance and sponsorships: https://openinfra.dev/summit/
    The OpenInfra Foundation builds communities that write open source infrastructure software that runs in production.

Noxopharm Phase I Clinical Trial Shows Anti-Inflammatory Response in COVID-19 Patients

Retrieved on: 
Wednesday, August 25, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious Diseases, Clinical Trials, Monash University, Virus, Therapy, TBK1, NYR, Coronavirus, Dexamethasone, RNA, Orthornavirae, Inflammation, Septic shock, NOX, Safety, Risk, ASX, Patient, Monash, Hudson, COVID-19, Hudson Institute, Prednisone, Drug development, Pharmaceutical industry

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has released preliminary top-line data from its NOXCOVID Phase I clinical trial testing the suitability of idronoxil ( Veyonda ), a TBK1 (TANK-binding kinase 1) inhibitor, as an anti-inflammatory in patients with moderate COVID-19 disease.

Key Points: 
  • Australian clinical-stage drug development company Noxopharm (ASX:NOX) has released preliminary top-line data from its NOXCOVID Phase I clinical trial testing the suitability of idronoxil ( Veyonda ), a TBK1 (TANK-binding kinase 1) inhibitor, as an anti-inflammatory in patients with moderate COVID-19 disease.
  • Based on initial positive results, Noxopharm has started discussions to add Veyonda to one of the global clinical trial programs looking at identifying effective anti-inflammatory therapies in COVID-19 disease.
  • The NOXCOVID Phase I clinical trial is highly encouraging for Veyonda in this role as a high proportion of the patients were experiencing elevated inflammation, said Noxopharm CEO and Managing Director Graham Kelly .
  • In this trial, no major safety issues were identified and 37 of 38 patients hospitalized with moderate respiratory disease recovered.

Immutep Reveals a New Anti-LAG-3 Research Program

Retrieved on: 
Tuesday, June 8, 2021
Geography of Wales, Wales, Immutep, LAG3, Cardiff, Monash, Geography of the United Kingdom, Frédéric Triebel

Professor Andrea Brancale of Cardiff University also added: Our collaboration with Immutep is a great opportunity to combine a diverse set of skills from multiple teams in what is an exciting area of research.

Key Points: 
  • Professor Andrea Brancale of Cardiff University also added: Our collaboration with Immutep is a great opportunity to combine a diverse set of skills from multiple teams in what is an exciting area of research.
  • Under the Agreement, all intellectual property relating to lead compounds as well as derivatives thereof, will be jointly owned by Immutep and Cardiff University.
  • Immutep will have exclusive rights to develop and commercialise the new molecules in the clinic according to pre-defined licensing terms.
  • As announced on 31 August 2020, the Australian Research Council (ARC) awarded Immutep and research partner Monash University a grant under the ARCs Linkage Project scheme to support their research collaboration into LAG-3 for a further three years.

Thermo Fisher Scientific Accelerates Complex Materials Research at Monash University with Specialized 300kV (S)TEM Microscope

Retrieved on: 
Thursday, May 20, 2021
Science, Branches of biology, Electron microscopy, Thermo Fisher Scientific, Electron microscope, Monash University, Transmission electron microscopy, MicroScope, Thermo, Fisher Scientific, Monash

b'HILLSBORO, Ore., May 20, 2021 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, has developed acustom-built high-resolution scanning transmission electron microscope ((S)TEM) to support advanced materials research at Monash University.

Key Points: 
  • b'HILLSBORO, Ore., May 20, 2021 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, has developed acustom-built high-resolution scanning transmission electron microscope ((S)TEM) to support advanced materials research at Monash University.
  • "Monash is home to an extensive network of world-leading research technology platforms, in-house support and expertise available to our research community and collaborators.
  • "\n"We are thrilled about our ongoing collaboration with Monash University and the opportunity to design a custom-built microscope that will advance materials science," said Rosy Lee, vice president of materials science at Thermo Fisher.
  • "\nThermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion.